{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:44:26Z","timestamp":1792586666614,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MHLW Research on Promotion of Cancer Control Program","award":["JPMH23EA1037"],"award-info":[{"award-number":["JPMH23EA1037"]}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K02589"],"award-info":[{"award-number":["24K02589"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Agency for Medical Research and Development (AMED) Practical Research for Innovative Cancer Control","award":["24015073"],"award-info":[{"award-number":["24015073"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multigene panel testing (MGPT) is usually discussed as a diagnostic technology. Its more important role, however, is to enable a proactive stance toward inherited cancer risk\u2014using an individual\u2019s germline information to go on the offensive against cancer rather than waiting for it to declare itself. Reframed this way, MGPT is the engine of stratified, preemptive cancer medicine: care that acts on genetic risk to intercept cancer before it arises. Framed by the definition of cancer genomic medicine\u2014care that optimizes treatment, predicts prognosis, and prevents disease onset using genomic information from the tumor and germline of patients with cancer, sometimes extending to unaffected individuals and to multi-omics information beyond the genome\u2014preemptive medicine is placed at the center; the Japanese Society for Hereditary Tumors, in its 2025 Guidance\u2014which spans diagnosis, prevention, and treatment across 56 genes\u2014provides the map for this approach in Japan. At its heart is the preventive arm: cascade testing and the fiscal-year 2026 reimbursement revision carry protection to unaffected pathogenic variant carriers before cancer begins, in a \u201cleave-no-one-behind\u201d model of cancer control. This review then examines how this continuum is delivered (team-based care, with attention to disparities), enabled (quality assurance, Japan\u2019s framework for laboratory-developed tests (LDTs), and social implementation through insurance), and\u2014central to this feature\u2014how it must integrate host biology. Because treatment optimization depends on whether the host can benefit, sarcopenia assessment is a natural preemptive companion to germline testing\u2014the host-biology foundation on which treatment is optimized, so that germline genetics and host biology are integrated rather than read in isolation.<\/jats:p>","DOI":"10.1007\/s10147-026-03210-z","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:11:53Z","timestamp":1792584713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multigene panel testing for hereditary tumor syndromes: an engine for stratified, preemptive cancer medicine in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-5488","authenticated-orcid":false,"given":"Akira","family":"Hirasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"3210_CR1","unstructured":"Council for the Promotion of Cancer Genomic Medicine (2017) Report: toward building citizen-participatory cancer genomic medicine. Ministry of Health, Labour and Welfare, Tokyo. https:\/\/www.mhlw.go.jp\/content\/10808000\/0000169236.pdf. Accessed Sep 2026. (in Japanese)"},{"key":"3210_CR2","unstructured":"Japanese Society for Hereditary Tumors (2025) Guidance for multigene panel testing (MGPT) for hereditary tumor syndromes. 2025 Edition. https:\/\/jsht-info.jp\/en\/wp-content\/uploads\/2026\/05\/HP_MGPT_20260429.pdf. Accessed Aug 2026. (English)"},{"key":"3210_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-026-02078-x","author":"S Belhadj","year":"2026","unstructured":"Belhadj S, Hatch CJ, LaDuca H et al (2026) Sequencing approaches in hereditary cancer testing: strengths, limitations and future directions. Eur J Hum Genet. https:\/\/doi.org\/10.1038\/s41431-026-02078-x","journal-title":"Eur J Hum Genet"},{"issue":"21","key":"3210_CR4","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.24.00662","volume":"42","author":"N Tung","year":"2024","unstructured":"Tung N, Ricker C, Messersmith H et al (2024) Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol 42(21):2599\u20132615. https:\/\/doi.org\/10.1200\/JCO.24.00662","journal-title":"J Clin Oncol"},{"key":"3210_CR5","doi-asserted-by":"publisher","unstructured":"Nielsen SM, Eccles DM, Romero IL et al (2018) Genetic testing and clinical management practices for variants in non-BRCA1\/2 breast (and breast\/ovarian) cancer susceptibility genes: an international survey by the ENIGMA Clinical Working Group. JCO Precis Oncol 2:PO.18.00091. https:\/\/doi.org\/10.1200\/PO.18.00091","DOI":"10.1200\/PO.18.00091"},{"key":"3210_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyag095","author":"I Imoto","year":"2026","unstructured":"Imoto I, Takaiso N, Yoshimura A et al (2026) Hereditary cancer multigene panel testing in the United States and Europe: real-world constraints and implications for responsible integration in Japan. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyag095","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"3210_CR7","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.gim.2023.100866","volume":"25","author":"DT Miller","year":"2023","unstructured":"Miller DT, Lee K, Abul-Husn NS et al (2023) ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing. Genet Med 25(8):100866","journal-title":"Genet Med"},{"issue":"25","key":"3210_CR8","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer (OlympiA). N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"22","key":"3210_CR9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer (PROfound). N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"1","key":"3210_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer (KEYNOTE-158). J Clin Oncol 38(1):1\u201310","journal-title":"J Clin Oncol"},{"key":"3210_CR11","doi-asserted-by":"publisher","unstructured":"Monroe M, Naik H, Ford JM et al (2026) Knowledge and attitudes on germline pharmacogenomic testing among clinical oncologists. Germline and somatic pharmacogenomics in precision oncology. JCO Precis Oncol. 10:e2600353 https:\/\/doi.org\/10.1200\/PO-26-00353","DOI":"10.1200\/PO-26-00353"},{"key":"3210_CR12","unstructured":"Onishi H, Health, Labour and Welfare Sciences Special Research Project group (2025) Research toward the clinical implementation of laboratory-developed tests (LDTs). Ministry of Health, Labour and Welfare, Tokyo. https:\/\/mhlw-grants.niph.go.jp\/project\/180619. Accessed Aug 2026 (in Japanese)"},{"issue":"7","key":"3210_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours. Lancet Oncol 9(7):629\u2013635","journal-title":"Lancet Oncol"},{"key":"3210_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB et al (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367","journal-title":"Eur J Cancer"},{"key":"3210_CR15","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M et al (2018) Cancer-associated cachexia. Nat Rev Dis Prim 4:17105","journal-title":"Nat Rev Dis Prim"},{"issue":"19","key":"3210_CR16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1200\/JCO.21.00102","volume":"39","author":"GR Williams","year":"2021","unstructured":"Williams GR, Dunne RF, Giri S et al (2021) Sarcopenia in the older adult with cancer. J Clin Oncol 39(19):2068\u20132078","journal-title":"J Clin Oncol"},{"key":"3210_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00031-7","volume":"8","author":"MC Zillikens","year":"2017","unstructured":"Zillikens MC, Demissie S, Hsu YH et al (2017) Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nat Commun 8:80. https:\/\/doi.org\/10.1038\/s41467-017-00031-7","journal-title":"Nat Commun"},{"issue":"8","key":"3210_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/dmcn.12777","volume":"57","author":"KMD Cornett","year":"2015","unstructured":"Cornett KMD, North KN, Rose KJ et al (2015) Muscle weakness in children with neurofibromatosis type 1. Dev Med Child Neurol 57(8):733\u2013736. https:\/\/doi.org\/10.1111\/dmcn.12777","journal-title":"Dev Med Child Neurol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03210-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:11:55Z","timestamp":1792584715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03210-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":18,"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03210-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"24 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}